New Era for Hemophilia Care in the UAE: Pfizer Introduces First Prefilled Injectable Therapy

By Editor_wr On May 8, 2025
Pfizer announced today the launch of a new and innovative therapy for people living with hemophilia in the UAE. This marks a significant advancement in care for individuals affected by this rare and serious bleeding disorder.
Hemophilia is a rare genetic bleeding disorder in which the blood fails to clot properly, leading to prolonged bleeding that can be either spontaneous or occur after an injury[1]. Unlike traditional clotting factor replacements, Pfizer's new therapy targets the tissue factor pathway inhibitor (TFPI), a natural anticoagulant protein. By inhibiting TFPI, the treatment helps restore balance to the body's clotting process, reducing the frequency of bleeding episodes.
This advanced therapy is administered once a week through a simple injection under the skin using a prefilled autoinjector pen. It is the first prefilled injectable therapy available in the UAE, designed to make treatment more convenient and accessible for patients, while reducing the burden of frequent infusions.
Dr. Nadine Tarcha, Pfizer Gulf Medical Director, said: 'The introduction of this therapy reflects Pfizer's ongoing commitment to improving the lives of people with rare diseases. By combining scientific innovation with a more convenient delivery method, we aim to empower individuals with hemophilia to live with greater confidence and improved quality of life.'
According to the World Federation of Hemophilia's 2023 Annual Global Survey[2], more than 32,000 in the Eastern Mediterranean region have been diagnosed with hemophilia. This represents less than half of the expected number of cases, suggesting that many individuals remain undiagnosed or lack access to appropriate care. These findings emphasize the importance of early diagnosis and patient-friendly treatment options that can support better long-term outcomes.
The introduction of this therapy supports the UAE's broader healthcare vision, which prioritizes access to innovative treatments and improved quality of care for people living with complex and rare conditions.
Patients are encouraged to speak with their healthcare provider to determine whether this treatment may be appropriate for their condition.
Comments are closed.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Gulf Business

13-06-2025

• Gulf Business

Tunisia's Health Minister on why the ‘One Health' agenda is key to MENA's health transformation

Image: Supplied Regional partnerships and integrated health strategies are playing a critical role in transforming public health systems across North Africa and the Eastern Mediterranean, Tunisia's Minister of Health, Mustapha Ferjani, said in an interview with Gulf Business ahead of the upcoming 'One Health, One Future' regional In a wide-ranging discussion, Ferjani highlighted the impact of Saudi Arabia's development funding in Tunisia's underserved areas, lessons from intra-regional collaboration, and the importance of embedding the 'One Health' framework — linking human, animal, and environmental health — into national policies. He also outlined Tunisia's efforts in operationalising the approach through legislative reform, capacity building, and cross-sectoral coordination. As Tunisia prepares to host the summit co-organised with the World Bank and the Quadripartite, Ferjani called for deeper regional alignment, data sharing, and coordinated efforts to build resilient health systems and respond to emerging challenges. The Saudi Fund for Development (SFD) has recently deepened its healthcare engagement in Tunisia, funding key hospital projects in underserved regions. How do you view the broader role of such regional development partnerships in transforming public health infrastructure across North Africa and the Eastern Mediterranean? Regional partnerships in MENA are strategically vital for the development of different sectors including public health in countries such as Tunisia. Investments from high-income countries, such as Saudi Arabia, are particularly beneficial as they foster shared growth while leveraging a deep understanding of regional contexts and specific challenges in comparison to international investments. The SFD's funding of key hospital projects in underserved regions of Tunisia, such as Sbiba (Kasserine Governorate) and El Jem (Mahdia Governorate), with an overall commitment of over $1.23bn in soft loans and grants for various development projects, including significant contributions to healthcare, directly addresses critical needs and disparities in healthcare access. We see the broader role of such regional development partnerships as transformative for public health infrastructure across the MENA region by bridging critical infrastructure gaps and expanding healthcare capacity, particularly in underserved areas, thereby enhancing service quality through the integration of modern technologies and international best practices. These collaborations promote sustainable development by building resilient healthcare systems with long-term operational frameworks. Tunisia's collaboration with the SFD is part of a growing trend of intra-regional investment in health and development. What lessons can be drawn from Tunisia's experience that could be replicated in other MENA countries, especially those facing similar healthcare access challenges? Tunisia's collaboration with the SFD demonstrates how successful intra-regional development partnerships are, especially when built on targeted investment, long-term commitment, comprehensive capacity building, and most importantly local ownership. Among the key lessons that can be drawn from Tunisia's experience and that are highly replicable in other MENA countries facing similar public health challenges, is directing investments towards underserved regions to address geographical disparities in health and ensure an expanded equitable healthcare delivery. Our Tunisian Saudi partnership also highlights the value of a long-term commitment and sustainable funding mechanisms, as such financial support allows for comprehensive planning and greater project longevity. Strong local ownership and seamless alignment with national health strategies, is another key lesson to be considered by other countries to ensure that external funding complements existing national plans and capacities, accelerating the transformation of public health infrastructure and improving healthcare access for millions. With the upcoming 'One Health, One Future' conference for the North Africa and Eastern Mediterranean region, how do you see the 'One Health' framework shaping national health strategies across the region? Are there any current examples in Tunisia where this integrated approach has already been adopted or piloted? Tunisia Ministry of Health foresees the 'One Health' framework playing an increasingly central and transformative role in shaping national health strategies across North Africa and the Eastern Mediterranean. Our upcoming 'One Health, One Future' conference for the region is meant to accelerate the adoption of comprehensive One Health national strategies and foster greater inter-sectoral collaboration, moving away from siloed approaches in public health, veterinary medicine, and environmental protection. Demonstrating a long-standing commitment to this integrated vision, Tunisia has prioritised efforts towards One Health. As early as 1994, well before the concept was formally established, the National Committee on Anthropozoonosis was created and then an early-warning system for avian influenza was established in 2000, combining border screening, farm testing, and wetland bird monitoring. Following the ratification of the Paris Agreement in 2016, Tunisia's ambitious Nationally Determined Contribution to the UNFCCC further integrated environmental protection, climate resilience, and public health. Our commitment to One Health was also evident in the finalisation of the National Action Plan on Antimicrobial Resistance (AMR) in 2018, which led to scaled-up AMR monitoring to include fish, dairy, and meat. By 2019, cross-sectorial collaborations between the Ministries of Health, Commerce and Agriculture lead to Law 25 on the sanitary safety of food products. More recently, in 2022, Tunisia launched a new legislative project led by its national One Health committee and established the One Health Laboratory at Tunis Pasteur Institute. Later in December 2023, the Ministry of Health joined efforts again with other Ministries to draft the joint One Health national roadmap, setting clear objectives for improved surveillance and coordinated response. This commitment extends to capacity building, with Tunisian veterinarians completing FAO's One Health courses, and practical applications such as our successful rabies elimination campaigns, which achieved over 80 per cent canine vaccination coverage in 2024 through free, mandatory vaccination and nationwide educational campaigns. Most recently, in 2025, Tunisia partnered with the World Bank to develop a Budgetary Action Plan further anchoring One Health in national planning. Dr Tedros, the DG of WHO (left) with Mustapha Ferjani, Minister of Health of Tunisia (right). Photo credit – World Health Organization Given the interconnected nature of human, animal, and environmental health in the region — particularly in rural and agricultural communities — what are the key capacity-building priorities to make 'One Health' a functional and sustainable model in Tunisia and beyond? We aim to transform the 'One Health' approach into a dynamic driver for research, innovation, and resilience-building. To achieve this, regional platforms for collaborative research must be strengthened, and innovation encouraged by establishing effective networks that include researchers, physicians, veterinarians, agricultural engineers, environmental scientists, economists, and data experts. We also seek to enhance data sharing, jointly set regional priorities, and develop impactful collaborative projects. Furthermore, we call for launching master's and doctoral programmes in 'One Health' within regional universities, through the preparation of joint training modules covering human medicine, veterinary medicine, environmental sciences, and public health. In conclusion, we aspire to make 'One Health' a true lever for action, innovation, and resilience across our region. How do you envision regional collaboration evolving post-conference? Could we see more institutional alignment, cross-border initiatives, or even regional task forces to advance the 'One Health' agenda collectively across the Arab world? Hosted by the government of Tunisia and co-organised with the World Bank and the Quadripartite (WHO, FAO, UNEP, WOAH), we envision that our 'One Health, One Future' conference for the North Africa and Eastern Mediterranean region to provide a strong push towards greater institutional alignment and regional collaboration around the One Health agenda. With the anticipated 'Carthage Declaration ', this landmark event is designed to be a catalyst for deeper, more structured cooperation across the Arab world and aims to mainstream One Health from dialogue to action. This means fostering formal agreements and common operational frameworks among health, agriculture, and environment ministries and agencies across the countries in the region. We also foresee increased collaboration in tackling shared challenges, such as conducting joint disease surveillance activities along common borders, coordinated vaccination campaigns against transboundary zoonosis, collaborative research efforts into regional health determinants, as well as effective cross-border data sharing and risk assessments. Tunisia's past engagement with Libya on zoonotic disease prioritisation and participation in Africa CDC's One Health workshops are early examples of this trend, which we expect to intensify with our One Health MENA Conference. We also hope to see more countries in the region adopting national One Health roadmaps, similar to Tunisia's recent initiative, that are harmonized with regional priorities and international standards. Read:

Zawya

21-05-2025

• Zawya

International and regional experts focus on RSV prevention at Pfizer MERA Maternal Immunization Summit

The Pfizer Middle East, Russia and Africa (MERA) Maternal Immunization Summit: Born Ready brought together more than 80 medical experts, physicians, and healthcare professionals together in Cairo, Egypt to share insights on the latest efforts to prevent RSV in newborns The summit highlighted the critical role of maternal vaccinations in the successful prevention of RSV and shed light on global best practices for such vaccination programs. Dubai, UAE – More than 80 international and regional healthcare experts have convened at the Pfizer MERA Maternal Immunization Summit: Born Ready to discuss issues pertaining to maternal immunization. The summit, entitled 'RISE: Respiratory Immunization Summit for Excellence' and, held from 16-17 May 2025 in Cairo, Egypt, focused on the growing burden of neonatal respiratory syncytial virus (RSV) and the role of maternal vaccination in its successful prevention. The summit aimed to increase awareness of the virus and its impact, in addition to the importance of maternal immunization in preventing RSV and protecting newborns. Experts addressed the challenges and barriers to the adoption of maternal immunization, shared best practices, and explored how healthcare providers can more effectively implement maternal immunization programs in the region. Professor Irene Cetin, Professor of Obstetrics and Gynecology, University of Milan and Head of Obstetrics, Mangiagalli Policlinico Hospital Fondazione IRCCS Cà Granda, Milan, Italy, said: 'Maternal immunization leverages the natural pregnancy process whereby antibodies – disease-fighting molecules – pass naturally from mother to baby through the placenta, starting in the second trimester and peaking during the third. Maternal antibodies help protect infants at birth and during the first few months of life, before they are eligible to receive vaccinations themselves.' The administration of a vaccine to an expectant mother activates the maternal immune system, triggering the production of immunoglobin G (IgG) antibodies, which pass through the placenta from the parental bloodstream. Professor Mohamed Momtaz, Emeritus Professor of Obstetrics and Gynecology, Kasr Al Ainy Faculty of Medicine, Cairo University, Cairo, Egypt, said: 'Because of the way the placenta pumps antibodies into the fetus during the second and third trimesters of pregnancy, fetal IgG concentration usually exceeds the concentration of antibodies in the maternal circulation in full-term infants, meaning the baby is better protected from infectious diseases than the mother. This highlights the tremendous potential of maternal immunization to help prevent transmission of communicable diseases and reduce the impact of infections such as RSV. Furthermore, events like this summit encourage evidence-based conversations between healthcare providers and expectant mothers, while also highlighting practical approaches to communication and appropriate data sharing.' According to the World Health Organization, RSV – a seasonal virus that leads to infections of the lungs and respiratory tract – is the most common cause of acute lower respiratory infections in children globally [i], responsible for an estimated 33 million such infections, more than three million hospitalizations and almost 60,000 deaths per year in children under 5 years of age [ii]. This trend is reflected regionally, where RSV infections are the leading cause of acute respiratory tract infections in young children, typically peaking during the winter months or the rainy season in humid countries. Professor Hossam Al Tatari, Director of General Pediatrics and Pediatric Infectious Diseases Services at The Heart Medical Center, Al Ain, UAE said: 'RSV infection is very common, affecting almost all children within two years from birth. In adults and older, healthy children, RSV typically produces mild symptoms that mimic the common cold, but in the newborn babies below 6 months, and those otherwise immunocompromised, such as babies born prematurely, the infection can prove life-threatening. It is imperative that we explore every possible avenue to mitigate the risks associated with RSV, and take every step to prevent transmission, especially to the most vulnerable amongst us.' Highlighting the benefits of maternal immunization to newborns and immunocompromised infants, Dr Hammam Haridy, Senior Director Regional Medical & Scientific Affairs at Pfizer MERA said: 'Infections such as RSV, while potentially dangerous, are preventable with vaccination. Despite the significant impact of RSV in the region and across the globe, comprehensive and consistent region-wide surveillance and burden data across the Middle East and North Africa region are currently limited. Forums such as the Maternal Immunization Summit are therefore crucial to drive buy-in of healthcare providers in order to increase awareness and tackle vaccine hesitancy. By providing a platform via which stakeholders can connect and share data and insights, we can drive the conversation around maternal vaccination, ensuring we make best use of available data in our interactions.' Both the World Health Organization and the Strategic Group of Experts on Immunization recommend countries adopt measures to prevent severe RSV in infants [iii], with decisions on whether to use maternal immunization or monoclonal antibodies dependent upon a number of factors. Emphasizing the need for collaboration between the medical community and vaccine developers to ensure maximum success in prevention, Merih Cetinkaya, Professor of Pediatrics, Health Sciences University and Head of Neonatology at Basaksehir Cam Sakura, City Hospital, Istanbul, Turkey, said: 'Communicable diseases such as RSV have considerable impact on neonatal health, affecting both our populations and our healthcare systems, and vaccinations remain a cornerstone in lessening this impact. As healthcare providers, we share responsibility with stakeholders across the healthcare landscape to understand such diseases, to leverage innovation and technology, and to ensure equitable access to life-saving vaccines, especially for the most vulnerable members of our communities.' During the event, Pfizer underscored its ongoing commitment to shaping the future of public health through the power of vaccines. Over the years, Pfizer's vaccines have played a vital role in preventing, controlling, and in some cases nearly eradicating infectious diseases, safeguarding millions of lives around the world and across the MERA region. As a leader in biopharmaceutical innovation, the company remains deeply invested in research and development, driving forward new solutions with the aim of enhancing patient outcomes and advancing global health. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at

Hi Dubai

13-05-2025

• Hi Dubai

UAE Leads Launch of Global Nursing Report with WHO in Regional Spotlight

The UAE has taken center stage in shaping the future of global healthcare by hosting the Eastern Mediterranean launch of the 'State of the World's Nursing 2025' report in collaboration with the World Health Organization (WHO). The virtual event, held by the Ministry of Health and Prevention (MoHAP) and Emirates Health Services (EHS), brought together senior officials and health leaders from across the region. Unveiled in conjunction with International Nurses Day, the report presents a comprehensive review of the global nursing workforce and outlines strategic recommendations to tackle pressing challenges, including an anticipated shortfall of 4.1 million nurses by 2030. The findings reveal stark disparities, with 78% of nurses concentrated in countries serving only 49% of the global population. Dr. Mohammed Salim Al Olama, MoHAP Undersecretary, said the report provides a forward-looking roadmap to strengthen nursing across the region. He highlighted the UAE's continued leadership since contributing to the first SoWN report in 2020, noting that its national strategy for nursing and midwifery is aligned with global standards and underpinned by innovation and advanced technologies. Dr. Yousif Mohamed AlSerkal, Director-General of EHS, emphasized the UAE's commitment to empowering nurses and ensuring sustainable, high-performing healthcare systems. He said the UAE's involvement reflects its long-term investment in healthcare talent and its role in driving regional and global progress. Dr. Sumaya Al Blooshi, head of the National Committee for Nursing and Midwifery, called the UAE's hosting of the launch a testament to its efforts in building a modern, institutional framework for the profession. The report also underscores the urgent need for policy reforms and international cooperation to ensure equitable healthcare access worldwide. News Source: Emirates News Agency